(Q42953218)

11 November 2017

title

Medical oncology: Optimizing chemotherapy and radiotherapy for anaplastic glioma (English)

1 reference

11 November 2017

1 reference

1 reference

Patrick G Morris

1

1 reference

11 November 2017

Andrew B Lassman

series ordinal

2

1 reference

11 November 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

Nature Reviews Clinical Oncology

11 November 2017

published in

1 reference

11 November 2017

volume

7

1 reference

11 November 2017

issue

8

1 reference

11 November 2017

page(s)

428-430

1 reference

https://scigraph.springernature.com/pub.10.1038/nrclinonc.2010.98

11 November 2017

exact match

0 references

cites work

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.98

Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.98

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.98

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.98

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.98

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.98

Survey of treatment recommendations for anaplastic oligodendroglioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.98

10.1038/NRCLINONC.2010.98

31 March 2020

Identifiers

DOI

1 reference

Dimensions Publication ID

11 November 2017

1048146787

0 references

1 reference